Literature DB >> 10809856

Once weekly fluconazole is effective in children in the treatment of tinea capitis: a prospective, multicentre study.

A K Gupta1, N Dlova, P Taborda, N Morar, V Taborda, C W Lynde, N Konnikov, M Borges, N Raboobee, R C Summerbell, P Adam, S L Hofstader, J Aboobaker.   

Abstract

In an open, multicentre evaluation carried out in Brazil, Canada and South Africa we have demonstrated that fluconazole 8 mg kg-1 once weekly is effective in tinea capitis caused by Trichophyton and Microsporum species. There were 61 children, aged (mean +/- SE) 5.0 +/- 0.3 years; weight (mean +/- 5.6) 20.0 +/- 0.9 kg; 41 males, 20 females; one Asian, 57 Black, one Caucasian and two Hispanic. The organisms were Trichophyton violaceum (33 patients), T. tonsurans (11) and Microsporum canis (17). The extent of tinea capitis at pretherapy was: mild (18 patients), moderate (30) and severe (13). Patients with tinea capitis due to Trichophyton species were initially treated for 8 weeks with an extra 4 weeks of fluconazole if clinically indicated. All 44 patients with tinea capitis due to Trichophyton species were completely cured (clinically and mycologically) when evaluated 8 weeks after completion of active treatment, following 8 weeks of once weekly dosing in 35 patients and 12 weeks of once weekly dosing in nine patients. In Microsporum canis tinea capitis, an extra 4 weeks was administered at week 12 in patients where it was clinically indicated at the time. Sixteen of 17 patients with M. canis tinea capitis were completely cured (clinically and mycologically) when evaluated 8 weeks following the end of treatment when given for 8, 12 and 16 weeks in 12, one and three patients, respectively. Overall, complete cure (clinical and mycological) occurred in 60 of 61 patients at follow-up 8 weeks from the end of therapy. The duration of once weekly fluconazole in the 60 patients was 8 weeks (47 patients), 12 weeks (10 patients) and 16 weeks (three patients), respectively. Clinical adverse effects consisted of a mild, reversible gastrointestinal complaint in three (4.9%) of 61 children. A laboratory abnormality with elevated liver function tests was observed in one (5.9%) of 17 patients; this was asymptomatic, and reversible. No patient discontinued therapy. The data suggest that once weekly fluconazole dosing is effective, safe and associated with high compliance when used to treat tinea capitis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10809856     DOI: 10.1046/j.1365-2133.2000.03479.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  8 in total

1.  Current Management of Onychomycosis and Dermatomycoses.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-10       Impact factor: 3.725

2.  Tinea capitis in infants: recognition, evaluation, and management suggestions.

Authors:  Brent D Michaels; James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2012-02

3.  Rectal fluconazole for tinea capitis.

Authors:  Jeffrey M Pernica; Natalie Dayneka; Charles Ps Hui
Journal:  Paediatr Child Health       Date:  2009-11       Impact factor: 2.253

4.  Isolation of Trichophyton violaceum and Trichophyton soudanense in Baltimore, Maryland.

Authors:  Shelley S Magill; Liliana Manfredi; Andrew Swiderski; Bernard Cohen; William G Merz
Journal:  J Clin Microbiol       Date:  2006-12-06       Impact factor: 5.948

Review 5.  Update in antifungal therapy of dermatophytosis.

Authors:  Aditya K Gupta; Elizabeth A Cooper
Journal:  Mycopathologia       Date:  2008-05-14       Impact factor: 2.574

6.  Management of tinea capitis in childhood.

Authors:  Antoni Bennassar; Ramon Grimalt
Journal:  Clin Cosmet Investig Dermatol       Date:  2010-07-14

7.  Intra-antral application of an anti-fungal agent for recurrent maxillary fungal rhinosinusitis: a case report.

Authors:  Adekunle D Dunmade; Olushola A Afolabi; Biodun S Alabi; Segun Segun-Busari; Olubisi A Koledoye
Journal:  J Med Case Rep       Date:  2012-08-20

Review 8.  Safety of fluconazole in paediatrics: a systematic review.

Authors:  Oluwaseun Egunsola; Abiodun Adefurin; Apostolos Fakis; Evelyne Jacqz-Aigrain; Imti Choonara; Helen Sammons
Journal:  Eur J Clin Pharmacol       Date:  2013-01-17       Impact factor: 2.953

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.